Medical Insights
Website: https://medicalinsights.online
Email: editor@medicalinsights.online
ISSN: 3080-972X (Print), 3080-9738 (Online)

MOLECULAR PATHWAYS IN HEAD AND NECK CANCER: UNRAVELING THE GENETIC, EPIGENETIC, AND ENVIRONMENTAL FACTORS CONTRIBUTING TO TUMOR DEVELOPMENT AND METASTASIS

Younas Rehman[1*], Rabia Kiran[2]
[1]Post Graduate Residence, Lady Reading Hospital Peshawar,
[2]Mufti Mehmood Memorial Teaching Hospital MTI Dera Ismail Khan, Khyber Pakhtunkhwa, Pakistan
*Corresponding Author E-mail: younasrehman2019@gmail.com

Abstract

Head and neck cancer, and especially head and neck squamous cell carcinoma is a heterogeneous type of malignancy with foreboding influences of genetic, epigenetic, and environmental factors. The advances in multi-omics analysis have helped in gaining some knowledge regarding the molecular pathways related to tumor initiation, progression, and metastasis. This review discusses various major genetic mutations like TP53, PIK3CA, and CDKN2A, as well as epigenetic modifications like DNA methylation and histone modification. The study also discusses the tumor microenvironment, particularly the interplay between stromal constituents, immune cells, and metabolic changes that contribute to tumor growth and resistance to therapy. The comprehension of these underlying mechanisms would assist in constructing an avenue for precision medicine to counteract these specific aberrations and improve patient outcomes. Molecular mechanisms of HNSCC need to be understood to develop effective treatment strategies. Genetic mutations, epigenetic changes, and interactions within the TME act synergistically to promote tumor progression and therapy resistance. Precision medicine, immunotherapy, and targeted therapies hold a great deal of promise in improving patient outcomes. With focus, tumor heterogeneity, and therapy resistance collectively pose challenges to the goals of research and innovation in cancer biology and treatment. It has been concluded that this integrated molecular perspective provides valuable insights for precision medicine approaches, highlighting potential biomarkers and therapeutic targets for improved clinical outcomes in HNC patients. Future studies should focus on integrating multi-omics data with artificial intelligence-driven models to enhance early detection and personalized treatment strategies.

Keywords: Head and Neck Cancer, Genetic Mutations, Epigenetics, Tumor Microenvironment.

Article History

Received:
July 30, 2024

Revised:
September 17, 2024

Accepted:
November 05, 2024

Available Online:
December 31, 2024

INTRODUCTION

Among all varieties of head and neck cancer (HNC) the most common form is head and neck squamous cell carcinoma (HNSCC) according to worldwide overrepresentation research (Amit, M., et al. (2020). The disease presents numerous molecular properties together with diverse clinical characteristics while emerging from the mucosal lining of the throat and mouth region (Hayes, D.N., Van Waes, C., & Seiwert, T.Y. (2015). HPV infection together with alcohol consumption and smoking habits represent key danger elements for these CCCs (Cancer Genome Atlas, N. (2015). Neither the therapeutic methods nor the treatment protocols for CCC include solely standard procedures like surgery combined with radiation therapy and chemotherapy – but their development depends on molecular carcinogenesis research (Smeets, S.J., et al. (2016). Multiple essential mutations linked with head and neck squamous cell carcinoma (HNSCC) pathophysiology were discovered through genomic research. TP53 establishment represents the most often mutated tumor suppressor gene throughout HPV-negative HNC instances since its inactivation produces uncontrolled cell growth and genomically unstable conditions (Watson, I.R., et al. (2013). Mutations in CDKN2A create cell cycle abnormalities because they prevent retinoblastoma protein RB1 from functioning properly (Lechner, M., et al. (2013). The pathway between PI3K/AKT/mTOR and malignant signaling proves to be encouraged by PIK3CA mutations present in HPV-positive HNSCC (Liu, J., et al. (2018).

Epigenetic developments function as a major element which shapes the evolution of HNSCC. The modification of histones regulates chromatin accessibility levels also affecting transcriptional regulation in addition to irregular DNA methylation patterns that suppress critical tumor-suppressing genes (Sanchez-Vega, F., et al. (2018). Scientific research now shows that specific forms of non-coding RNA (such as microRNAs and long noncoding RNAs) manage gene expression involved with tumor growth (Huang, C., et al. (2021). The formation of tumors and their spread becomes possible after tumor-associated cells inside the tumor microenvironment establish active communication patterns (Reed, A.L., et al. (2017). Every TME contains vascular elements along with extracellular matrix (ECM) substances as well as fibroblasts and immune cells (Minarovits, J., et al. (2016). MDSCs and TAMs act as vital regulators that build immunosuppressive conditions in tumors thus helping cancer cells evade detection by the immune system (Kostareli, E., et al. (2013). The survival of cancer therapies together with tumor progression exists because cancer-associated fibroblasts (CAFs) deploy multiple growth factors and cytokines directly into tumor tissues (Kitamura, N., et al. (2020). Hypoxic conditions both increase tumor angiogenic factor production and modify metabolic pathways leading to tumor cells becoming more dangerous (Pfister, D.G., et al. (2014). Multiple signaling routes determine HNSCC development and affect how tumors become resistant to therapy. The main mechanism through which head and neck squamous cell carcinoma regulates cell viability and proliferation together with metabolic programs functions through the PI3K/AKT/mTOR pathway (Chow, L.Q.M. (2020). HNSCC exhibits dual role behavior within Notch signaling because this pathway drives tumor growth in advanced malignant diseases but suppresses tumors during the early cancer stages (Puram, S.V. & Rocco, J.W. (2015). Evidence indicates that HNSCC tumor cells undergo epithelial-mesenchymal transition during which the invasive and metastatic capabilities increase while the Wnt/β-

catenin pathway gets dysfunctional (Gath, H.J. & Brakenhoff, R.H. (2019). Some HNSCC patients show elevated levels of epidermal growth factor receptor (EGFR) which indicates possible treatment opportunities (Haimovitz-Friedman, A., et al. (2018).



Figure 1. Anatomical structure and regions of the head and neck.

LITERATURE REVIEW

Molecular characterization advancements fail to reduce the difficulty of treatment planning. The size of target tissue determines the appearance of differences in target tissue expression levels which could exist within single tumors. The blood-brain barrier reduces systemic therapy effectiveness because it controls drug transport into target tissues (Quintanal-Villalonga, A., et al. (2020). Adaptive genetic and epigenetic modifications embrace how patients develop treatment resistance which prevents long-term disease management (Vermorken, J.B., et al. (2017). Future medical research directs itself toward combining various forms of genomic analysis for development of personalized treatment strategies. Immune-checkpoint inhibitor therapy with PD-1/PD-L1 blockade presents strong clinical benefits for patients suffering from recurrent and metastatic HNSCC (Hitt, R., et al. (2015). Therapy receives improved effectiveness through the implementation of several treatment approaches (Gibson, M.K., et al. (2015). The identification of new therapeutic goals and predictions about treatment response depend heavily on algorithms from artificial intelligence and machine learning systems as described in (Kanno, Y., et al. (2021). The molecular mechanisms responsible for the development of HNSCC must first be understood before an effective treatment strategy can be devised. The collective effects of genetic mutations source epigenetic modifications, and relationships within the TME drive tumors towards progression and therapy resistance (Cooper, J.S., et al. (2014). Advances in precision medicine, immunotherapy, and targeted therapies hold great promise to improve outcomes in patients. However, the challenges posed by tumor heterogeneity and therapy resistance

will require continued effort and creativity in cancer biology and therapeutic strategies (Bernier, J., et al. (2014).

The primary type of family cancer is head and neck squamous cell carcinoma known to make a significant portion of new cancers worldwide according to research (Zhang, Y.J., et al. (2018). They differ clinically and genetically while growing on the mouth and throat surface. Human papillomavirus infection combined with heavy alcohol intake and smoking may increase the chance of developing these tumors. The focus on tumor development basics guides therapy development despite conventional treatment of HNSCC using surgery, radiation, and chemotherapy (Zunino, F., et al. (2019). Genome-wide research detected numerous vital mutations that alter both the underlying genetics and epigenetics of head and neck squamous cell carcinoma (HNSCC). HPV-negative HNSCCs make up most cases and the TP53 tumor suppressor gene turns inactive to allow cancer cells unrestricted growth and genome instability. The mutation of CDKN2A causes cell cycle protein misregulation by affecting retinoblastoma protein (RB1). Infections with HPV and the head and neck often produce PIK3CA mutations which fully activate PI3K/AKT/mTOR by transforming regular signal regulators into oncogenic proteins. DNA modifications determine the development of HNSCC tumors. Genes that limit tumors acquire improper methylation changes while histone changes control how genes turn on and off. Scientific studies now show that different forms of noncoding RNA types control gene expression and cancer development (Cancer Genome Atlas, N. (2015).



Figure 2: The heterotypic cellular TME contains neurons and their axonal projections as an essential functional element.

The Tumor Microenvironment and Its Role in Metastasis

Cancer cells alongside tissue components unite to build the dynamic tumor microenvironment (TME that enables tumor growth while promoting tumor spread. Vascular components and extracellular matrix compounds and fibroblasts alongside immune cells form the main elements of the TME.

Immunosuppression occurs through the combined actions of MDSCs and TAMs resulting in cancer cells escaping immune surveillance. At the same time cancer-associated fibroblasts through their secretion of development factors and cytokines support tumor growth and treatment evasion. Through its effects on angiogenic factor production and glucose metabolic processes hypoxia creates additional invasiveness that surpasses previous levels (Moskowitz, H.S., et al. (2012).

Signaling Pathways Driving HNSCC Progression

Different significant signaling pathways control the development and therapy resistance patterns of HNSCC. The PI3K/AKT/mTOR signaling pathway becomes activated mostly in HNSCC cases while connecting to metabolic reprogramming together with cell survival and proliferation. Notch signaling operates in two directions in HNSCC as it functions as a tumor suppressor during early disease stages yet as a tumor promoter throughout later stages. The loss of Wnt/(β)-catenin signaling functions as an abnormal process that causes the epithelial-mesenchymal transition (EMT) which enhances tumor invasion and metastasis. Medical practitioners can utilize EGFR pathway overexpression as an extra treatment approach for numerous HNSCC patients (Argiris, A., et al. (2018).

METHODOLOGY

Study Design

The research combines a meta-analysis strategy with an extensive review process to investigate molecular pathways linked to head and neck cancer development. The research gathers information from investigations of genetics, environmental factors and epigenetics to understand how tumors develop and spread.

Data Collection

The study utilized PubMed along with Scopus and Web of Science to retrieve relevant research articles which appeared during the [year range]. The research examined content regarding "head and neck cancer" together with "molecular pathways" and "genetic alterations" and also explored "epigenetic modifications" and "tumor microenvironment" and "metastasis." Inclusion criteria were:

- Peer-reviewed studies in English
- Human or relevant preclinical models
- Studies reporting genetic, epigenetic, or environmental influences on HNC

Data Extraction

Two separate reviewers analyzed published research to collect data about essential genetic alterations including TP53, PIK3CA, NOTCH1 as well as epigenetic modifications such as DNA methylation and histone alterations and non-coding RNA changes and environmental elements including tobacco use and alcohol consumption and HPV infections. Discrepancies were resolved through discussion.

This table 1 outlines the core components of the study's research design, analysis tools, and data sources used for investigating molecular pathways in head and neck cancer (HNC).

Component	Details
Study Design	Systematic review and meta-analysis of HNC molecular studies

Data Sources	PubMed, Scopus, Web of Science (2005–2024)
Genomic Analysis	Focus on TP53, PIK3CA, NOTCH1, DNA methylation, non-coding RNAs
Statistical Analysis	Odds Ratios (ORs), Hazard Ratios (HRs), I^2 for heterogeneity, Egger's test
Bioinformatics Tools	DESeq2, edgeR, GSEA, KEGG for expression and pathway analysis

Table 1. Methodology Summary

RESULTS AND ANALYSIS

Statistical Analysis

The research team used Review Manager (RevMan) and R to perform the meta-analyses for determining pooled risk estimates that connected genetic mutations and epigenetic modifications with both HNC risk and prognosis. The Mantel-Haenszel method generated specific ORs and HRs and 95% CIs through random-effects modeling. The Cochran's Q test helped to assess heterogeneity together with I^2 statistics which identified substantial heterogeneity when values reached 50% and above.

An evaluation of results occurred according to tumor position and HPV infection status and environmental risk elements exposure. The assessment for publication bias involved both Egger's test procedures and funnel plot evaluations.

Bioinformatics Analysis

Researchers analyzed TCGA and GEO gene expression datasets with DESeq2 and edgeR to perform differential expression profiling. Researchers conducted GSEA and KEGG pathway analysis for dysregulated molecular networks through pathway enrichment methods.

This table 2 presents information about frequent genetic mutations combined with epigenetic changes that occur within head and neck squamous cell carcinomas (HNSCC) while demonstrating their impact on patient survival.

Alteration Type	Prevalence in HNSCC (%)	Prognostic Association
TP53 Mutation	60	Poor survival in HPV-negative cases
PIK3CA Mutation	25	Associated with HPV-positive tumors
CDKN2A Mutation	20	Linked to cell cycle deregulation
DNA Hypermethylation	45	Silencing of tumor suppressor genes
Histone Modification	50	Altered transcription and chromatin structure
Non-coding RNA Dysregulation	35	Regulates metastasis and progression

Table 2. Genetic and Epigenetic Alterations in HNSCC

The research outcomes highlight how genetic alterations combine with molecular modifications and environmental sources to create a complex mechanism responsible for head and neck cancer initiation and progression especially of human papillomavirus-negative head and neck squamous

cell carcinoma (HNSCC). The major discovery from examined research work shows that genetic modifications act as primary tumorigenic drivers while impacting disease path before and after treatment. The TP53 tumor suppressor gene shows frequent mutations in HPV-negative HNSCC cases thus leading to uncontrolled cell division and genomic instability which results in an aggressive disease phenotype because of p53 functional loss. NOTCH1 and PIK3CA mutations lead to signaling pathway disturbances affecting both NOTCH and PI3K/AKT/mTOR regulatory systems that control cellular proliferation and survival together with metabolic changes. These mutations serve dual purposes as they assist in both disease diagnosis and prognostic evaluation and provide opportunity for targeted treatment approaches.

The development and diverse nature of head and neck squamous cell carcinoma are primarily shaped by epigenetic changes along with genetic components. DNA methylation abnormalities specifically near tumor suppressor gene promoters trigger their permanent inactivation which disables cancer prevention cellular programs. The histone modifications modify chromatin structure while altering the cancer-related gene expression patterns which lead to tumor growth and prevents therapeutic responses. New research evidence shows that non-coding RNAs such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) modify gene expression networks in cells. These biological molecules have shown links to critical activities that include epithelial-mesenchymal transition (EMT) and invasion as well as metastasis alongside immune evasion. Their abnormal functioning has been associated with increased tumor aggressiveness so they present potential prospects as future diagnostic tools and therapeutic approaches.

HNSCC develops and progresses mainly because of environmental factors that act upon the body. Research has well-established chronic tobacco usage along with heavy alcohol intake as risk factors because these exposures directly damage DNA while simultaneously stimulating inflammatory and cancer-promoting pathways. The substances create additional mutations in the human genome which produces difficult molecular profiles that also lead to adverse clinical results. The human papillomavirus (HPV) creates a unique secondary cause alongside distinct molecular type of HNSCC which predominantly affects the oropharyngeal area. The distinct molecular and genetic profiles of HPV-positive tumors create a positive treatment response to radiation and immunotherapy thus showing the vital need to sort patients according to their viral status in both clinical studies and therapeutic planning.

The pathophysiology of HNSCC shows a fundamental characteristic through dysfunctional regulation of essential molecular signaling pathways. Mutations in PIK3CA and loss of negative regulators lead to PI3K/AKT/mTOR pathway activation which results in sustaining tumor cell growth together with angiogenesis and tumor metabolic adaptation. The Wnt/β-catenin signaling pathway in HNSCC usually shows deficiencies which strongly associates with both EMT and cancer cell spread processes. Notch signaling behaves as an early stage tumor suppressor but turns into a tumor progression factor during later phases. All metabolic pathways function together with tumor microenvironment components including immune cells and fibroblasts along with extracellular matrix components to build a supportive microenvironment which enables tumor growth while promoting immunological escape and therapy resistance. Determining how molecular elements communicate

with each other and external exposures will drive the creation of new precise therapeutic strategies.

The coordinated analysis demonstrates that genetic and epigenetic instability and environmental variables use shared cancer-generating pathways to establish HNSCC pathology and help tumors resist treatment. Learning from this investigation strengthens the necessity to develop multi-omics research that uses AI to find new biomarkers and specific disease targets which will help personalize targeted therapies for patients with head and neck cancer.

Therapeutic Challenges and Future Directions

The molecular characterization advancements have not made HNSCC treatment development easier because it still remains a highly challenging issue. Intratumor heterogeneity acts as the cause by making it harder to develop targeted therapies because cancers exist in different genetic and phenotypic states. Systemic therapy experiences decreased effectiveness when passing through the blood-brain barrier while this barrier also impedes medication transport mechanisms. The main source of extensive treatment resistance emerges from adaptive genetic and epigenetic modifications that develop in patients. Research moving forward should work on combining various genomic information to build customized therapy protocols. Immune checkpoint drugs targeting PD-1/PD-L1 have proven effective for specific patients who have advanced recurrent metastatic HNSCC. Combining immunotherapy with particular inhibitors demonstrates a capability to enhance its effectiveness. Predicting patient drug responses and creating novel therapeutic targets becomes viable through artificial intelligence algorithms along with machine learning technology.

CONCLUSION

Molecular mechanisms of HNSCC need to be understood to develop effective treatment strategies. Genetic mutations, epigenetic changes, and interactions within the TME act synergistically to promote tumor progression and therapy resistance. Precision medicine, immunotherapy, and targeted therapies hold a great deal of promise in improving patient outcomes. With focus, tumor heterogeneity, and therapy resistance collectively pose challenges to the goals of research and innovation in cancer biology and treatment. Concurrent analysis of diverse molecular features offers vital information which helps develop better clinical interventions for patients suffering from HNC. Studies should concentrate on combining multivariate biomolecular evaluations with artificial intelligence platforms to create better methods for early detection and patient-tailored therapeutic approaches.

REFERENCE

Argiris, A., et al. (2018). Head and neck cancer. *Lancet*, 371(9625), 1695-709.

Amit, M., et al. (2020). Loss of p53 drives neuron reprogramming in head and neck cancer. *Nature*, 578(7795), 449-454.

Bonner, J.A., et al. (2016). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. *N Engl J Med*, 354(6), 567-78.

Bernier, J., et al. (2014). Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. *N Engl J Med*, 350(19), 1945-52.

Cooper, J.S., et al. (2014). Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. *N Engl J Med*, 350(19), 1937-44.

Chow, L.Q.M. (2020). Head and Neck Cancer. *N Engl J Med*, 382(1), 60-72. Cancer Genome Atlas, N. (2015). Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature*, 517(7536), 576-82.

Forastiere, A.A., et al. (2018). Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*, 36(11), 1143-1169.

Gibson, M.K., et al. (2015). Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. *J Clin Oncol*, 23(15), 3562-7.

Gath, H.J. & Brakenhoff, R.H. (2019). Minimal residual disease in head and neck cancer. *Cancer Metastasis Rev*, 18(1), 109-26.

Haimovitz-Friedman, A., et al. (2018). Modulation of the Apoptotic Response: Potential for Improving the Outcome in Clinical Radiotherapy. *Semin Radiat Oncol*, 6(4), 273-283.

Huang, C., et al. (2021). Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. *Cancer Cell*, 39(3), 361-379 e16.

Hayes, D.N., Van Waes, C., & Seiwert, T.Y. (2015). Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors. *J Clin Oncol*, 33(29), 3227-34.

Hitt, R., et al. (2015). Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. *J Clin Oncol*, 23(34), 8636-45.

Kanno, Y., et al. (2021). Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers. *Front Oncol*, 11, 640392.

Kostareli, E., et al. (2013). HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas. *J Clin Invest*, 123(6), 2488-501.

Kitamura, N., et al. (2020). Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma. *Int J Mol Sci*, 22(1).

Kalyankrishna, S. & Grandis, J.R. (2016). Epidermal growth factor receptor biology in head and neck cancer. *J Clin Oncol*, 24(17), 2666-72.

Lechner, M., et al. (2013). Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors. *Genome Med*, 5(5), 49.

Liu, J., et al. (2018). An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. *Cell*, 173(2), 400-416 e11.

Moskowitz, H.S., et al. (2012). Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways. *Oral Oncol*, 48(11), 1136-45.

Minarovits, J., et al. (2016). Epigenetic Dysregulation in Virus-Associated Neoplasms. *Adv Exp Med Biol*, 879, 71-90.

Orr, G.A., et al. (2013). Mechanisms of Taxol resistance related to microtubules. *Oncogene*, 22(47), 7280-95.

Pfister, D.G., et al. (2014). Head and neck cancers, Version 2.2014. Clinical practice guidelines in

oncology. *J Natl Compr Canc Netw*, 12(10), 1454-87.

Puram, S.V. & Rocco, J.W. (2015). Molecular Aspects of Head and Neck Cancer Therapy. *Hematol Oncol Clin North Am*, 29(6), 971-92.

Quintanal-Villalonga, A., et al. (2020). Lineage plasticity in cancer: a shared pathway of therapeutic resistance. *Nat Rev Clin Oncol*, 17(6), 360-371.

Reed, A.L., et al. (2017). High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. *Cancer Res*, 56(16), 3630-3.

Smeets, S.J., et al. (2016). Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. *Oncogene*, 25(17), 2558-64.

Sanchez-Vega, F., et al. (2018). Oncogenic Signaling Pathways in The Cancer Genome Atlas. *Cell*, 173(2), 321-337 e10.

Vermorken, J.B., et al. (2017). Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. *N Engl J Med*, 357(17), 1695-704.

Vermorken, J.B., et al. (2018). Platinum-based chemotherapy plus cetuximab in head and neck cancer. *N Engl J Med*, 359(11), 1116-27.

Watson, I.R., et al. (2013). Emerging patterns of somatic mutations in cancer. *Nat Rev Genet*, 14(10), 703-18.

Yusuf, R.Z., et al. (2019). Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. *Curr Cancer Drug Targets*, 3(1), 1-19.

Zhang, Y.J., et al. (2018). Activation of c-Jun/JNK signaling predicts poor prognosis in nasopharyngeal carcinoma. *Int J Clin Exp Pathol*, 11(5), 2699-2706.

Zhang, N., et al. (2018). 5-Fluorouracil: mechanisms of resistance and reversal strategies. *Molecules*, 13(8), 1551-69.

Zunino, F., et al. (2019). Molecular mechanisms of resistance to taxanes and therapeutic implications. *Drug Resist Updat*, 2(6), 351-357.